Pharmacologıcal Requırements For Intravenous Sedatıon in Oncologıcal Patıents Undergoıng Chronıc Opıoıd Analgesıc Treatment Durıng Percutaneous Interventıonal Procedures
Abstract
Objective: To describe the pharmacological requirements of the doses used for fentanyl, propofol and midazolam, during intravenous sedation in oncology patients with chronic opioid analgesic treatment undergoing percutaneous interventional procedures.
Materials and methods: An observational, retrospective, cross-sectional, and descriptive study was conducted after obtaining approval from the Research and Ethics Committee. Information was obtained through the review of clinical records of patients undergoing interventional procedures for oncological pain at the Pain Clinic of the National Cancer Institute between March 1st, 2020, and February 29th, 2024. A descriptive statistical analysis was performed, followed by a bivariate analysis using Chi-square and ANOVA tests to identify the association between chronic opioid analgesic treatment and pharmacological requirements in our population.
Results: A total of 494 patients were studied, of whom 68.6% were female (n = 339) and 31.4% were male (n = 155). 99% of the patients were between 45 and 70 years of age, with a mean age of 57.66 years. The most frequently identified oncological diagnoses in our population were: breast cancer (20.4% of cases) (n = 101), multiple myeloma (14.2% of cases) (n = 70), and cervical cancer (12.6%) (n = 62).
Regarding opioid analgesic treatment for pain control prior to the interventional procedure (n=494), 438 patients (88.6%) were identified as receiving opioid treatment (average Morphine Equianalgesic Daily Dose:56 mg), while only 56 patients (11.3%) were not. We found a trend toward greater use of fentanyl during intravenous sedation in patients without chronic opioid use compared to the group of patients with chronic opioid use. With respect to midazolam and propofol, similar requirements were found between the groups. No significant correlation was identified between the dose of intravenous sedation drugs and chronic drug use.
Conclusions: There was no correlation on the average doses of midazolam, fentanyl and propofol in patients with chronic pain treatment who underwent percutaneous interventional procedures, regardless of whether they were on analgesic treatment or not. Prospective studies are required to corroborate these results.
Keywords: Opioids, percutaneous interventional procedures, cancer pain, intravenous sedation.
Keywords:
Opioids, percutaneous interventional procedures, Cancer pain, intravenous sedation.DOI
https://doi.org/10.22270/jddt.v15i5.7146References
1. Magee D, Bachtold S, Brown M, Farquhar-Smith P. Cancer pain: Where are we now? Pain Manag. 2018 Jan 1;9(1):63-79. https://doi.org/10.2217/pmt-2018-0031 PMid:30516438
2. (PDF) Consenso Mexicano de Manejo de Dolor por Cáncer. Available from: https://www.researchgate.net/publication/303874243_Consenso_Mexicano_de_Manejo_de_Dolor_por_Cancer
3. Van Den Beuken-Van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2016;51(6):1070-1090.e9. https://doi.org/10.1016/j.jpainsymman.2015.12.340 PMid:27112310
4. George B, Minello C, Allano G, Maindet C, Burnod A, Lemaire A. Opioids in cancer-related pain: current situation and outlook. Supportive Care in Cancer 2019 27:8 [Internet]. 2019;27(8):3105-18. https://doi.org/10.1007/s00520-019-04828-8 PMid:31127436
5. Russo MM, Sundaramurthi T. An Overview of Cancer Pain: Epidemiology and Pathophysiology. Semin Oncol Nurs [Internet]. 2019 ;35(3):223-8. https://doi.org/10.1016/j.soncn.2019.04.002 PMid:31085106
6. Kaye AD, Jones MR, Viswanath O, Candido KD, Boswell M V, Soin A, et al. Guidelines ASIPP Guidelines for Sedation and Fasting Status of Patients Undergoing Interventional Pain Management Procedures. 2019; Available from: www.painphysicianjournal.com
7. Practice guidelines for sedation and analgesia by non-anesthesiologists: An updated report by the American Society of Anesthesiologists task force on sedation and analgesia by non-anesthesiologists. Anesthesiology 2002;96(4):1004-17. https://doi.org/10.1097/00000542-200204000-00031 PMid:11964611
8. Dsouza RS, Warner MA, Olatoye OO, Langford BJ, Bruns DL, Schroeder DR, et al. Perioperative Opioid Consumption and Clinical Outcomes in Surgical Patients with a Pre-Existing Opioid-Based Intrathecal Drug Delivery System. Anesth Analg. 2022;134(1):35. https://doi.org/10.1213/ANE.0000000000005662 PMid:34260427 PMCid:PMC8678135
9. Silverman JE, Gulati A. An overview of interventional strategies for the management of oncologic pain. Pain Manag. 2018;8(5):389-403. https://doi.org/10.2217/pmt-2018-0022 PMid:30320541
10. Puijk RS, Ziedses Des Plantes V, Nieuwenhuizen S, Ruarus AH, Laurien, Vroomen GPH, et al. Propofol Compared to Midazolam Sedation and to General Anesthesia for Percutaneous Microwave Ablation in Patients with Hepatic Malignancies: A Single-Center Comparative Analysis of Three Historical Cohorts. Cardiovasc Intervent Radiol. 2019;42:1597-608. https://doi.org/10.1007/s00270-019-02273-y PMid:31243542 PMCid:PMC6775535
11. Simopoulos T, Leffler D, Barnett S, Campbell D, Lian SJ, Gill JS. Prospective Assessment of Pain and Comfort in Chronic Pain Patients Undergoing Interventional Pain Management Procedures. Pain Medicine. 2018;19(2):336-47. https://doi.org/10.1093/pm/pnx064 PMid:28431040
12. French R, Fellow P, Mchugh MD, Lake E, Scott JM, Margo J, et al. A Systematic Review of Care Needs for Surgical Patients with Chronic Opioid Use Chair for Nursing Education, Professor of Nursing Term Chair in Nursing and Health Policy, Professor of Nursing and Sociology HHS Public Access. Vol. 29, Medsurg Nurs. 2020.
13. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018;129(2):343. https://doi.org/10.1097/ALN.0000000000002130 PMid:29462012 PMCid:PMC6051899
14. Poço Gonçalves J, Veiga D, Araújo A. Chronic pain, functionality and quality of life in cancer survivors. Br J Pain. 2020;15(4):401. https://doi.org/10.1177/2049463720972730 PMid:34840788 PMCid:PMC8611292
15. Aboel Dahab A, El-Hag D, Moutamed GM, Aboel Dahab S, Abuknesha R, Smith NW. Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics. Cancer Chemother Pharmacol. 2016;78(3):465-89. https://doi.org/10.1007/s00280-016-3028-4 PMid:27061417
16. Burns SL, Majdak P, Urman RD. Perioperative and Periprocedural anesthetic management of opioid tolerant patients and patients with active and medically treated opioid use disorder. Vol. 35, Current Opinion in Anaesthesiology. Lippincott Williams and Wilkins; 2022. p. 514-20. https://doi.org/10.1097/ACO.0000000000001157 PMid:35788122 PMCid:PMC9308736
Published
Abstract Display: 206 
PDF Downloads: 269 PDF Downloads: 10 How to Cite
Issue
Section
Copyright (c) 2025 Ana Karen Castillo-Desaida , María del Rocio Guillén-Nuñez , Ángel Juárez-Lemus , Berenice Carolina Hernández Porras , Grezzia Isareyda Avellaneda-Peralta , Hectór Alberto Arámbula-Morones
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.